Comparison of fluorescence in situ hybridization and immunohistochemistry for assessment of HER-2 status in breast cancer patients

Abstract

The accurate assessment of a proto-oncogene, human epidermal growth factor receptor-2 gene (HER-2), is extremely important for the therapy and prognosis of breast cancer. Currently, immunohistochemistry (IHC) is the method widely used for the detection of HER-2 protein. Fluorescence in situ hybridization (FISH) has been suggested to be a golden standard assay for HER-2 amplification. This study examined the expression and amplification of HER-2 in paraffin-embedded sections of breast cancer tissues, and compared the two methods on the measurement of HER-2 status. HER-2 gene and protein were determined in breast cancer samples from 52 Chinese women by FISH and IHC respectively. The findings indicated that the HER-2 gene amplification was found in 18 cases (34.6%) by FISH and the HER-2 protein over-expression (score 3+) in 15 cases (28.8%) by IHC. Immunohistochemically, 28.6% of the cases scored as 2+ and 93.3% of the cases scored as 3+ were HER-2-positive by FISH. There was a significant correlation between the HER-2 gene amplification and HER-2 protein over-expression in breast cancer (P<0.005). No correlation was noted between the HER-2 gene amplification and any of the clinicopathological parameters examined, including age, menopausal status, menarche age, tumor size, histological tumor type, histological grade, lymph node status, and the expression of ER and PR. It was concluded that the detection of HER-2 gene amplification in breast cancer by FISH is valuable and can compare with HER-2 protein detection by IHC.

Keywords

HER-2 / fluorescence in situ hybridization / immunohistochemistry / breast cancer

References

[1] SlamonD.J., Leyland-JonesB., ShakS., et al. . Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001, 344(11): 783-792

[2] WolffA.C., HammondM.E., SchwartzJ.N., et al. . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med, 2007, 131(1): 18-43

[3] DolanM., SnoverD.. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice. Am J Clin Pathol, 2005, 123(5): 766-770

[4] LalP., SalazarP.A., HudisC.A., et al. . HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol, 2004, 121(5): 631-636

[5] KammoriM., KurabayashiR., KashioM., et al. . Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer. Oncol Rep, 2008, 19(3): 651-656

[6] MerolaR., MottoleseM., OrlandiG., et al. . Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis. Eur J Cancer, 2006, 42(10): 1501-1506

[7] KostopoulouE., VageliD., KaisaridouD., et al. . Comparative evaluation of non-informative HER-2 immunoreactions (2+) in breast carcinomas with FISH, CISH and QRT-PCR. Breast, 2007, 16(6): 615-624

[8] KuoS.J., WangB.B., ChangC.S., et al. . Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients. Taiwan J Obstet Gynecol, 2007, 46(2): 146-151

[9] Vincent-SalomonA., MacGroganG., CouturierJ., et al. . Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology, 2003, 42(4): 337-347

[10] HameedO., ChhiengD.C., AdamsA.L.. Does using a higher cutoff for the percentage of positive cells improve the specificity of HER-2 immunohistochemical analysis in breast carcinoma?. Am J Clin Pathol, 2007, 128(5): 825-829

[11] Vanden BemptI., VanhentenrijkV., DrijkoningenM., et al. . Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas. Histopathology, 2005, 46(4): 431-441

[12] VarshneyD., ZhouY.Y., GellerA.S., et al. . Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol, 2004, 121(1): 70-77

[13] ItohH., MiyajimaY., UmemuraS., et al. . Lower HER-2/chromosome enumeration probe 17 ratio in cytologic HER-2 fluorescence in situ hybridization for breast cancers. Cancer, 2008, 114(2): 134-140

[14] RasmussenB.B., AnderssonM., ChristensenI., et al. . Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002–2006. A nationwide study including correlation between HER-2 status and other prognostic variables. Acta Oncol, 2008, 47(4): 784-788

[15] NamB.H., KimS.Y., HanH.S., et al. . Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res, 2008, 10(1): R20